Australian Clinical Labs Ltd (AU:ACL) has released an update.
Australian Clinical Labs Limited (ACL) reported a steady FY24 with a total revenue of $696.4M and an underlying EBIT of $62.6M, maintaining performance despite a significant drop in COVID-19 revenue. The company announced an improved second half EBIT margin of 11% and a positive outlook with FY25 EBIT guidance set between $65M-$73M. Additionally, shareholders can look forward to a $0.09 fully franked final dividend, culminating in a total FY24 dividend of $0.12.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
